Advanced search×

Tumor necrosis factor alpha (TNF-@a), anti-TNF-@a and demyelination revisited: An ongoing story

Ana Caminero, Manuel Comabella, and Xavier Montalban

J Neuroimmunol 234(1-2):6 (2011) PMID 21474190

Tumor necrosis factor alpha (TNF-@a) is a cytokine with pleiotropic actions that can be present both as a transmembrane protein and soluble cytokine (sTNF). Both ligands interact with two different receptors, TNFR1 and TNFR2, which mediate their biological effects. TNF-@a is involved in the pathogenesis of multiple sclerosis (MS), however, administration of anti-TNF-@a agents to MS patients has been associated with increased disease activity. Insomuch as TNFR1 mediates demyelination and TNFR2 remyelination, it could be hypothesized that anti-TNF-@a agents which selectively inhibit sTNF or signals from TNFR1 could be effective in treating MS.

Copyright © 2011 Elsevier Ltd. All rights reserved.

DOI: 10.1016/j.jneuroim.2011.03.004
Version: za2963e q8zad q8zbb q8zc2 q8zd7 q8ze9 q8zfc q8zg1

Similar articles you may find interesting…

  1. Title Page/Editorial Board
    Author(s) unavailable

    J Neuroimmunol 211(1-2):iii (2009)

  2. Multiple sclerosis: current treatment algorithms.
    Jordi J Río, Manuel M Comabella, and Xavier X Montalban

    Curr Opin Neurol 24(3):230-7 (2011) PMID 21499098

    All of these medications have demonstrated partial efficacy along with different side-effect profiles. Nevertheless, many patients continue to experience disease activity while on treatment, and recommendations have been made on how the success of therapy in an individual patient can be assessed. SU...
  3. Immunomodulation by chronobiologically-based glucocorticoids treatment for multiple sclerosis relapses
    Lea Glass-Marmor, Tamar Paperna, ... Ariel Miller

    J Neuroimmunol 210(1-2):124-127 (2009) PMID 19329193

    This study compares the effects of daytime versus nighttime intravenous glucocorticoid treatment of multiple sclerosis (MS) relapses for several immune indicators. The levels of serum CRP, TNFalpha, ESR, MMP-2, MMP-9, TIMP-1, and TIMP-2 were determined at trial entry and at day 7 post therapy initia...